CompletedPhase 3NCT00293124
Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors
Studying Gastrointestinal stromal tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Central European Cooperative Oncology Group
- Principal Investigator
- Thomas Brodowicz, MDUniversity Clinic of Internal Medicine I / Clinical Oncology
- Intervention
- Glivec(drug)
- Enrollment
- 125 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2004 – 2008
Study locations (16)
- AKH, Universitätsklinik für Innere Medizin 1, Vienna, Austria
- Institute of Oncology Sarajevo, Sarajevo, Bosnia and Herzegovina
- SBALO National Oncology Center, Sofia, Bulgaria
- National Oncological Center Hospital, Sofia, Bulgaria
- Sofia Cancer Center compl. Mladost ,, Sofia, Bulgaria
- Clinical Hospital Split, Center of Oncology, Split, Croatia
- University Hospital Rebro, Zagreb, Croatia
- FN Bulovka, Prague, Czechia
- Radioterapeticko-onkologicke. Oddeleni FN Motol, Prague, Czechia
- Lithuanian Oncology Center,, Vilnius, Lithuania
- Institutul Oncologic Bucuresti, Bucharest, Romania
- Institutul Oncologic Cluj, Cluj-Napoca, Romania
- Emergency Clinical County Hospital , Clin Oncol. Dep, Craiova, Romania
- Institut za onkologiju i, Belgrade, Serbia
- National Institute of Oncology, Bratislava, Slovakia
- +1 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00293124 on ClinicalTrials.govOther trials for Gastrointestinal stromal tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07434843PH 2 Pemigatinib in SDH-deficient GISTDana-Farber Cancer Institute
- RECRUITINGPHASE1NCT07171203Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal TumorUniversity of California, San Diego
- ENROLLING BY INVITATIONPHASE2NCT07550582Mesenteric Vascular Preconditioning Combined With Laparoscopic and Endoscopic Cooperative Surgery for Submucosal Tumor at the Gastroesophageal JunctionPeking University People's Hospital
- RECRUITINGPHASE2NCT07406633KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line SettingKumquat Biosciences Inc.
- RECRUITINGNANCT07405125Safety of Robotic Surgery for GISTs at Special Anatomic SitesThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE3NCT07218926A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib TherapyGlaxoSmithKline
- RECRUITINGPHASE1, PHASE2NCT07096609Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST PatientsAsan Medical Center
- RECRUITINGPHASE2NCT07559864Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard TreatmentJian Li